Microsulis's microwave ablator approved in Canada
This article was originally published in Clinica
Health Canada has approved the Acculis Accu2i percutaneous microwave tissue ablation (pMTA) system, developed by Microsulis Medical, for the coagulation of soft tissue during surgical procedures. The Acculis Accu2i delivers 2.45GHz of power to coagulate unwanted tissue masses, and consists of a 1.8mm diameter closed water-cooled needle. The Denmead, UK company CE marked the system in February 2010 for the treatment of liver and lung tumours, and it gained US clearance in August for the same indication (www.clinica.co.uk, 19 August 2010).
You may also be interested in...
Dr Noam Emanuel is the founder and chief technology officer of Ness Ziona, Israel-based drug delivery firm PolyPid. The 15-strong firm, established in 2008, has developed an encapsulation technology which allows the precise targeting of drug release.
Mesoblast has received the all-clear from the US FDA to start a Phase III clinical trial for bone marrow regeneration in patients with blood cancers. The study will be conducted together with Mesoblast's strategic alliance partner, Cephalon, which will fund the trial.
Mesoblast has received the green light from the US FDA to begin a Phase II trial of its proprietary adult mesenchymal precursor cell (MPC) product for the treatment of degenerative disc disease, a major cause of chronic low back pain.